Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial

1 Feb 2024

Abstract excerpt

The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle-invasive bladder cancer (MIBC). Before commencing the GUSTO trial, we needed to determine the reliability of a commercial subtyping platform (Decipher Bladder; Veracyte) when performed in an external trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Colorectal Cancer Screening and Detection
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40525454
DOI: 10.1002/2056-4538.12363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trialPMID 40525454Read ↗

Immunohistochemical assays for bladder cancer molecular subtyping: Optimizing parsimony and performance using Lund taxonomySemantic proximity Read ↗

International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4Semantic proximity Read ↗

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Molecular subtyping of invasive bladder cancer: time to divide and rule?Semantic proximity Read ↗

Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy ClassifiersSemantic proximity Read ↗

A versatile and upgraded version of the LundTax classification algorithm applied to independent cohortsSemantic proximity Read ↗

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.Semantic proximity Read ↗

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.Semantic proximity Read ↗

Deep Learning Bridges Histology and Transcriptomics to Predict Molecular Subtypes and Outcomes in Muscle-Invasive Bladder CancerSemantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.Semantic proximity Read ↗

The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.